These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23515515)

  • 1. Leakage from closed-system transfer devices as detected by a radioactive tracer.
    De Ausen L; DeFreitas EF; Littleton L; Lustik M
    Am J Health Syst Pharm; 2013 Apr; 70(7):619-23. PubMed ID: 23515515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
    Garrigue P; Montana M; Ventre C; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Int J Pharm Compd; 2016; 20(2):148-54. PubMed ID: 27323425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal
    Kicenuik K; Northrup N; Dawson A; Locke J; Villamil JA; Chretin J; Sfiligoi G; Clifford C; Rosenberg M; Hamilton T; Regan R; Parsons-Doherty M; Mallett C; Philibert J; Impellizeri J; Hofmeister E
    Vet Comp Oncol; 2017 Mar; 15(1):163-173. PubMed ID: 25864458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of unintended volume loss of six closed system transfer devices.
    Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W
    J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A test method for assessment of spill and leakage from drug preparation systems.
    Nygren O; Gustavsson B; Eriksson R
    Ann Occup Hyg; 2005 Nov; 49(8):711-8. PubMed ID: 16126763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs).
    Besheer A; Mahler HC; Matter-Schwald A; Barrenechea SM; Vogt M; Chalus P; Heymes P; Pillow T; Kirste A; Favrod P; Joerg S; Mathaes R
    Pharm Res; 2020 Apr; 37(4):81. PubMed ID: 32274594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.
    Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S
    Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of closed system transfer devices for turnaround time and ease of use.
    Nurgat ZA; Lawrence M; Elhassan TA; Al Nahedh M; Ashour M; Alaboura D; Al-Jazairi AS; Al-Jedai A
    J Oncol Pharm Pract; 2019 Jul; 25(5):1142-1151. PubMed ID: 29958506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
    Sumikawa S; Yakushijin Y; Aogi K; Yano T; Hiroki ; Hashimoto ; Tsukui C; Noguchi T; Shiraishi T; Horikawa Y; Yasuoka Y; Tanaka A; Hidaka N; Tanaka M
    Sci Rep; 2022 Jan; 12(1):139. PubMed ID: 34996936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pressure Compatibility Test of Closed System Drug Transfer Devices for 71 Anticancer Drugs].
    Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K
    Yakugaku Zasshi; 2021; 141(1):143-150. PubMed ID: 33390441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing a protocol for the compatibilities of closed-system transfer devices with multiple chemotherapy drugs under simulated clinical conditions.
    Chiang SC; Shen M; Lin CC; Chang HP
    PLoS One; 2021; 16(9):e0257873. PubMed ID: 34582474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational exposure to anti-cancer drugs: A review of effects of new technology.
    Vyas N; Yiannakis D; Turner A; Sewell GJ
    J Oncol Pharm Pract; 2014 Aug; 20(4):278-87. PubMed ID: 23975555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syringe plunger contamination by hazardous drugs: a comparative study.
    Smith ST; Szlaczky MC
    J Oncol Pharm Pract; 2014 Oct; 20(5):381-5. PubMed ID: 24598373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices.
    Soubieux A; Tanguay C; Bussières JF
    Eur J Hosp Pharm; 2021 Mar; 28(2):65-70. PubMed ID: 33608432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.